Akebia Therapeutics (AKBA) Stock Price, News & Analysis

Company Overview

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for patients with kidney disease and related complications. The company’s portfolio centers on therapies for anemia associated with chronic kidney disease (CKD), a condition that can result from reduced kidney function and insufficient production of erythropoietin.

Akebia’s primary product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In the United States, Vafseo is approved to treat anemia due to CKD in adults who have been receiving dialysis for at least three months. The product is designed to stimulate the body’s natural response to low oxygen levels and support red blood cell production.

The company also markets Auryxia (ferric citrate), which is approved in the United States for controlling serum phosphorus levels in adults with CKD on dialysis and for treating iron-deficiency anemia in certain adults with non-dialysis-dependent CKD. Akebia gained Auryxia through its combination with Keryx Biopharmaceuticals in 2018. The company is headquartered in Cambridge, Massachusetts, and serves patients primarily through its commercial operations in the United States, while pursuing international opportunities through partnerships and licensing arrangements.

John P. Butler has served as Akebia’s president and chief executive officer since 2016. The company’s operations and research activities remain focused on renal medicine, including the development and commercialization of therapies intended to address significant unmet needs among people with CKD.

Key Stats

• Today's Range: $0.77 to $0.80
• 50-Day Range: $0.77 to $1.29
• 52-Week Range: $0.77 to $3.20
• Volume: 6.50 million shs
• Average Volume: 6.68 million shs
• Market Capitalization: $213.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.90
• Consensus Rating: Hold

Akebia Therapeutics Stock Analysis - MarketRank™

Akebia Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 567th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Akebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Akebia Therapeutics has a consensus price target of $3.90, representing about 406.5% upside from its current price of $0.77.

Amount of Analyst Coverage

Akebia Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Akebia Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.27) per share.

Price to Book Value per Share Ratio

Akebia Therapeutics has a P/B Ratio of 6.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.48% of the float of Akebia Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Akebia Therapeutics has a short interest ratio ("days to cover") of 3.51, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Akebia Therapeutics has recently increased by 9.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akebia Therapeutics does not currently pay a dividend.

Dividend Growth

Akebia Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.47

News Sentiment

Akebia Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Akebia Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 5 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.30% of the stock of Akebia Therapeutics is held by insiders.

Percentage Held by Institutions

33.92% of the stock of Akebia Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AKBA
• CIK: 1517022
• Web: www.akebia.com
• Phone: (617) 871-2098
• Fax: 617-871-2099
• Employees: 194
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Akebia Therapeutics: $3.90
• High Price Target: $6.00
• Low Price Target: $1.00
• Potential Upside/Downside: +406.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.34 million
• Net Margins: -13.54%
• Pretax Margin: -12.71%
• Return on Equity: -88.88%
• Return on Assets: -7.74%

Debt

• Debt-to-Equity Ratio: 0.99
• Current Ratio: 1.43
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $236.20 million
• Price / Sales: 0.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.12 per share
• Price / Book: 6.42

Miscellaneous

• Outstanding Shares: 277,110,000
• Free Float: 265,190,000
• Market Cap: $213.37 million
• Optionable: Optionable
• Beta: 0.18